ScholarIQanswers from OpenAlex & ORCID
Messoud Ashina
ResearcherPublications, citations & collaboration network
Messoud Ashina is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Messoud Ashina have?
ScholarIQindexed works
Messoud Ashina has 553 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Messoud Ashina have?
ScholarIQcitation count
Messoud Ashina has 30,134 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Messoud Ashina?
ScholarIQh-index
Messoud Ashina has an h-index of 90 in OpenAlex.
What is the i10-index of Messoud Ashina?
ScholarIQi10-index
Messoud Ashina has an i10-index of 350 in OpenAlex.
What is the ORCID of Messoud Ashina?
ScholarIQorcid
The ORCID for Messoud Ashina is on the source record.
What is the OpenAlex record for Messoud Ashina?
ScholarIQopenalex
The OpenAlex for Messoud Ashina is on the source record.
What are the most-cited papers on Messoud Ashina?
ScholarIQmost cited works
Migraine: epidemiology and systems of care
Messoud Ashina, Zaza Katsarava, Thien Phu, Dawn C. Buse, Patricia Pozo‐Rosich, Aynur Özge, Abouch Valenty Krymchantowski, Elena R. Lebedeva, Krishnamurthy Ravishankar, Shengyuan Yu, Simona Sacco, Sait Ashina, Samaira Younis, Timothy J. Steiner, Richard B. Lipton
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Stewart J. Tepper, Messoud Ashina, Uwe Reuter, Jan Lewis Brandes, David Doležil, Stephen D. Silberstein, Paul Winner, Dean Leonardi, Daniel D. Mikol, Robert Lenz
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
David W. Dodick, Messoud Ashina, Jan Lewis Brandes, David Kudrow, Michel Lantéri‐Minet, V. В. Osipova, Kerry Palmer, Hernàn Picard, Daniel D. Mikol, Robert Lenz
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
Michel D. Ferrari, Hans‐Christoph Diener, Xiaoping Ning, Maja Galić, Joshua M. Cohen, Ronghua Yang, Matthias Müeller, Andrew H. Ahn, Yael Carmeli Schwartz, Melissa Grozinski‐Wolff, Lindsay Janka, Messoud Ashina